Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

NCT05754502 · clinicaltrials.gov ↗

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab emtansine

Sponsor

Consorzio Oncotech

Collaborators

[object Object]